Ten stocks capped off last week’s trading with eye-popping gains, thanks to a series of rallies in precious metals and positive clinical trial results, among others. Of the 10 firms, five notably notched new record highs.
In this article, we identify the 10 top-performing stocks last week and detail the reasons behind their gains.
To come up with the list, we focused exclusively on stocks with a $2 billion market capitalization and 5 million shares in trading volume.
The stocks were chosen based on the percentage changes in their prices on January 16 and 23, 2026.
The New York Stock Exchange building. Photo by Дмитрий Трепольский on Pexels
10. IAMGOLD Corp. (NYSE:IAG)
IAMGOLD grew its share prices by 22.01 percent week-on-week, as investor sentiment was primarily fueled by the record runs in prices of silver and gold and strong preliminary results for full-year 2025.
During the week, the stock rallied to a 14-year high, mimicking its mining counterparts and the spot prices of silver and gold, with the said metals clocking growth of 14.5 percent and 8.4 percent week-on-week, at $102.9 and $4,982.91.
Sentiment was further supported by IAMGOLD Corp.’s (NYSE:IAG) announcement earlier in the week that it was able to achieve its gold production target for full-year 2025, ending at 765,900 ounces, thanks to strong production from its Essakane, Cote, and Westwood sites.
Official results are scheduled to be announced after market close on February 17, 2026.
For this year, the company is targeting to hit gold production between 720,000 and 820,000 ounces, as it focuses on sustainable operations at nameplate levels ahead of an expansion plan set to be announced in the fourth quarter of the year.
In other news, several analysts issued a “buy” recommendation for shares of IAMGOLD Corp. (NYSE:IAG).
TD Securities gave the highest price target of $24, followed by Canaccord, which raised its price target to $23.32 from $11.05 previously. Bank of America, for its part, issued a $20.50 fair value assessment.
9. Orla Mining Ltd. (NYSEAmerican:ORLA)
Orla Mining grew its share prices by 25 percent week-on-week to hit a new all-time high, rallying alongside its counterparts after gold prices surged to a fresh peak and announcements of a record-breaking gold production performance last year.
In Friday’s trading alone, Orla Mining Ltd. (NYSEAmerican:ORLA) jumped to its highest price of $18.50 before paring gains to finish the session just up by 5.91 percent at $18.45 apiece.
This followed gold’s climb to the $4,900 level—a new record high, as precious metals, which are typically treated as safe assets, continued to attract investor interest amid ongoing geopolitical tensions and trade uncertainties between the US and its neighboring countries.
Sentiment was further supported by news earlier in the week that it exceeded its total production target last year, ending at 300,620 ounces versus its guidance of 265,000 to 285,000 ounces.
In the same year, Orla Mining Ltd. (NYSEAmerican:ORLA) sold as much as 297,013 ounces of gold.
“Thanks to the effort and dedication of our people across the business, we successfully exceeded our annual production guidance—delivering more than 300,000 ounces for the first time in our history. The strength of our diversified portfolio was clearly demonstrated in the second half of 2025, driven by outstanding execution by our operations teams in Mexico and Canada,” said Orla Mining Ltd. (NYSEAmerican:ORLA) President and CEO Jason Simpson.
8. Corcept Therapeutics Inc. (NASDAQ:CORT)
Corcept Therapeutics saw its share prices jump by 26.6 percent week-on-week, as investors took heart from the strong clinical trial results of its drug candidate, relacorilant, in patients with platinum-resistant ovarian cancer.
In an updated report, Corcept Therapeutics Inc. (NASDAQ:CORT) said that relacorilant, when combined with nab-paclitaxel chemotherapy, showed a 35 percent reduction in death risks in patients, as compared with those treated with nab-paclitaxel alone, during the third phase of its clinical trial. The therapy was able to cut disease progression by 30 percent.
The median overall survival for patients receiving relacorilant was 16 months, as compared with 11.9 months for those receiving nab-paclitaxel alone.
Corcept Therapeutics Inc. (NASDAQ:CORT) said that relacorilant, in combination with nab-paclitaxel, was well-tolerated, consistent with its known safety profile.
The trial enrolled a total of 381 patients with platinum-resistant ovarian cancer at sites in the United States, Europe, South Korea, Brazil, Argentina, Canada, and Australia. Patients were randomized 1:1 to receive either relacorilant plus nab-paclitaxel or nab-paclitaxel alone.
Corcept Therapeutics Inc. (NASDAQ:CORT) said that complete results from the study are set to be announced at an upcoming medical conference.
7. Almonty Industries Inc. (NASDAQ:ALM)
Almonty Industries grew its share prices by 28.25 percent week-on-week, hitting a new all-time high, as investors took heart from the company’s highly optimistic outlook for its tungsten business amid a limited global supply of the said metal.
In a letter to investors, Almonty Industries Inc. (NASDAQ:ALM) Chairman, President, and CEO Lewis Black announced that the company is planning to advance the Sangdong tungsten mine in South Korea toward full-scale phase 1 commercial operations, to be followed by a phase 2 expansion in 2027.
Upon completion, Almonty Industries Inc. (NASDAQ:ALM) expects the site to produce 460,000 MTU annually.
The Sangdong mine is expected to be one of the largest and longest-life tungsten mine sites outside of China, positioning the company as a cornerstone supplier to Western markets.
“We have secured binding hard floor offtake agreements, including long-term commitments to supply tungsten oxide for US defense applications, providing future revenue visibility and validating the strategic value of our production,” Lewis said.
Almonty Industries Inc. (NASDAQ:ALM) acquired the Sangdong mine when the US halted its mining operations in 2015. Since then, it has been working on bringing the site back into production.
6. IperionX Limited (NASDAQ:IPX)
IperionX saw its share prices jump by 28.4 percent week-on-week to end just a few cents shy of its all-time high, as investors took heart from its new deal with the US Army for the supply of 700 lightweight titanium components for the latter’s heavy ground combat systems.
On Friday, the stock surged to its highest price of $60.35, just $0.55 shy of its all-time high of $60.90 last October 15.
In a statement, IperionX Limited (NASDAQ:IPX) said that the deal, amounting to $300,000, has the potential to increase significantly upon successful delivery of the initial scope of work.
IperionX Limited (NASDAQ:IPX) said that replacing steel components with titanium is expected to reduce combat systems’ weight by 40 to 45 percent, or several hundred kilograms per vehicle, enabling faster acceleration and better agility, increased operational range and survivability, and reduced ground pressure, improving traction and flotation on soft or uneven terrain.
“IperionX is the only domestic US producer of commercial-scale primary titanium metal, a material that is designated as strategic and critical by the US Government,” IperionX Limited (NASDAQ:IPX) said.
“This purchase order directly supports US government priorities to reshore and secure critical materials supply chains, reduce reliance on foreign titanium sources, and expand domestic manufacturing capacity using recycled feedstocks,” it added.
5. TMC the metals company Inc. (NASDAQ:TMC)
TMC the metals company grew its share prices by 30.39 percent week-on-week as investors loaded portfolios following news that it sought another regulatory approval for its planned exploration of the Clarion Clipperton Zone’s (CCZ) international waters.
In a statement, TMC the metals company Inc. (NASDAQ:TMC) said that it submitted an application with the National Oceanic and Atmospheric Administration (NOAA) for the issuance of an exploration license and a commercial recovery permit for its planned exploration of a 65,000-square-kilometer area in the CCZ, markedly larger than the 25,000-km² coverage area applied for in April 2025.
“This new application represents the culmination of more than a decade of disciplined scientific, engineering, and environmental work. It translates years of exploration, testing, and data collection into a single, comprehensive submission for a defined, expanded, and game-changing critical minerals project, with more than 800 million estimated tonnes of nodules containing high-grade nickel, copper, cobalt and manganese—representing a metal grade of approximately 3.2 percent for nickel equivalent and 7 percent copper equivalent,” said TMC the metals company Inc. (NASDAQ:TMC) Chairman and CEO Gerard Barron.
“We believe it demonstrates both the maturity of our project and our readiness to proceed to commercial operations under the US regulatory framework,” he added.
TMC the metals company Inc. (NASDAQ:TMC) is originally a Canadian company, which last year earned the ire of several members of the International Seabed Authority (ISA) for allegedly bypassing Canada, an ISA member, and the agency, with its submission to the US.
In its defense, the listed firm said that the submission was made through its US subsidiary.
4. USA Rare Earth Inc. (NASDAQ:USAR)
USA Rare Earth jumped by 40.02 percent week-on-week, as investors cheered progress on the development of its Round Top Rare Earth Project in Sierra Blanca, Texas.
In a statement on Thursday, USA Rare Earth Inc. (NASDAQ:USAR) said that it tapped Fluor and WSP as its Engineering, Procurement, and Construction Management (EPCM) partners to advance the Definitive Feasibility Study for the said site.
The first phase of the study is targeted to be completed using results from its solvent extraction (SX) pilot work, which is currently underway at its facility in Wheat Ridge, Colorado.
At the same time, USA Rare Earth Inc. (NASDAQ:USAR) plans to operate its demonstration plant in Wheat Ridge, Colorado, for at least 2,000 continuous hours, with operations currently expected to conclude in October 2026.
In parallel, USA Rare Earth Inc. (NASDAQ:USAR) expects to carry out confirmatory and geotechnical drilling at Round Top in the first half of 2026, along with a heap leach optimization study, to support mine design and engineering.
Meanwhile, investors will closely watch out for how the company will perform when markets reopen on Monday, following news over the weekend that the US government is officially acquiring a $1.6 billion stake in the listed firm.
3. Americas Gold and Silver Corporation (NYSEAmerican:USAS)
Americas Gold and Silver Corp. soared by 43.36 percent week-on-week to hit a new 52-week high, as investors continued to load up portfolios in mining stocks amid precious metals’ surge to new all-time highs.
On Friday alone, Americas Gold and Silver Corporation (NYSEAmerican:USAS) jumped to its highest price of $9.41 before paring gains to end the day just up by 9.55 percent at $9.29 apiece.
This followed silver spot prices’ jump to the $103 territory, while gold rallied to as high as $4,988—just $12 shy of the $5,000 territory, during the session.
The rally in precious metals and mining stocks remained boosted by geopolitical tensions between the world’s largest economy and the European Union, despite both parties already recalling previously announced tariff plans, as investors stayed cautious amid a volatile and unpredictable US president.
Further fueling sentiment were news earlier that Americas Gold and Silver Corporation (NYSEAmerican:USAS) hit a record silver production of 2.65 million ounces, up 52 percent from 1.74 million ounces in 2024.
Its Cosala operations in Mexico alone achieved a new annual production record of 1.19 million ounces, driven by a record quarter output of 463,000 ounces for the fourth quarter of 2025.
“We capped off a highly successful and transformative 2025 with a 52 percent increase in attributable silver production to 2.65 million ounces—achieved in a robust and rising silver price environment that significantly amplifies the revenue and cash flow benefits of our expanded output,” said Chairman and CEO Paul Andre Huet.
2. Hycroft Mining Holding Corp. (NASDAQ:HYMC)
Hycroft grew its share prices by 46.3 percent week-on-week to notch a new all-time high, as investors loaded portfolios following silver and gold prices’ climb to record prices.
On Friday alone, Hycroft Mining Holding Corp. (NASDAQ:HYMC) jumped to its highest price of $51.47 before paring gains to end the day just up by 8.48 percent at $50.65 apiece. This as spot prices of silver cracked past the $103 level, while gold ran to as high as $4,988, or just $12 shy of the $5,000 territory.
The rally in precious metals and mining stocks was boosted by geopolitical tensions between the world’s largest economy and the European Union, despite both parties already recalling previously announced tariff plans, as investors stayed cautious amid a volatile and unpredictable US president.
Meanwhile, Hycroft Mining Holding Corp. (NASDAQ:HYMC) announced earlier that it had found the highest grades of silver in the Vortex Silver System at its Nevada site, and that drilling results in all depths and directions show continuity of resources.
Hycroft Mining Holding Corp. (NASDAQ:HYMC) is a US-based gold and silver producer exploring and developing one of the world’s largest precious metals deposits in Nevada.
1. Corvus Pharmaceuticals Inc. (NASDAQ:CRVS)
Corvus Pharmaceuticals soared by 211.8 percent week-on-week to hit a new all-time high, as investors cheered the strong results of its clinical trial testing the efficacy of soquelitinib in patients with moderate to severe eczema.
On Friday alone, the stock jumped to its highest price of $26.95 before giving up all gains to end the session down by 1.65 percent at $25.10 apiece.
In an updated report earlier in the week, Corvus Pharmaceuticals Inc. (NASDAQ:CRVS) said that its drug candidate successfully demonstrated a 72 percent reduction in the severity of enrolled patients’ eczema in the first phase trial, as compared with the 40 percent reduction for those who took the placebo.
Additionally, the therapy was observed to be even more effective when taken longer, and it was well-tolerated by enrolled patients.
Based on the positive results, Corvus Pharmaceuticals Inc. (NASDAQ:CRVS) is planning to initiate a Phase 2 trial in the first quarter of 2026 and enroll 200 patients with moderate-to-severe atopic dermatitis who have failed at least one prior topical or systemic therapy.
The trial is anticipated to enroll four cohorts of 50 patients each, with soquelitinib doses of 200 mg once per day, 200 mg twice per day, and 400 mg once per day, along with a placebo group.
The Phase 2 trial is targeted to run for 12 weeks with a 30-day follow-up period without treatment.
While we acknowledge the potential of CRVS to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than CRVS and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge fund investor letters by entering your email below.
